PetMed Express (Nasdaq: PETS ) is expected to report Q1 earnings around July 15. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict PetMed Express's revenues will grow 1.3% and EPS will increase 10.0%.
The average estimate for revenue is $69.9 million. On the bottom line, the average EPS estimate is $0.22.
Last quarter, PetMed Express reported revenue of $51.1 million. GAAP reported sales were 8.6% lower than the prior-year quarter's $55.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.23. GAAP EPS of $0.23 for Q4 were 21% higher than the prior-year quarter's $0.19 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 35.7%, 180 basis points better than the prior-year quarter. Operating margin was 14.2%, 300 basis points better than the prior-year quarter. Net margin was 9.0%, 190 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $231.4 million. The average EPS estimate is $0.87.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 873 members out of 902 rating the stock outperform, and 29 members rating it underperform. Among 234 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 229 give PetMed Express a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PetMed Express is hold, with an average price target of $11.92.
Is PetMed Express the right retailer for your portfolio? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average retailing powerhouse. Click here for instant access to this free report.
- Add PetMed Express to My Watchlist.